Last updated: February 21, 2026
What is the current status of Moxatag's clinical development and approval?
Moxatag (amoxicillin extended-release) is an oral antibiotic primarily used for bacterial infections. It is a branded version produced by GlaxoSmithKline (GSK). The drug's patents have expired, and generic versions are available. Despite its long-standing use, there are no recent active clinical trials or development initiatives explicitly targeting Moxatag as a new drug entity.
Key points:
- Moxatag marketed for streptococcal pharyngitis and sinusitis.
- Original patent expiring in the early 2010s.
- No recent high-profile clinical trials or regulatory filings reported.
- GSK no longer markets it as a separate standalone product; generic versions dominate.
What is the market landscape for Moxatag?
The Moxatag market is primarily driven by its active ingredient, amoxicillin. Its market dynamics diverge from new drug development to generics, which are characterized by low margins but high volume.
Market size and valuation
The global amoxicillin market was valued at approximately $1.2 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 3.2% projected through 2030. The growth is driven by increasing antibiotic use in emerging economies and high prevalence of bacterial infections.
| Attribute |
Detail |
| 2022 global value |
$1.2 billion |
| 2023-2030 CAGR |
3.2% |
| Major markets |
North America, Europe, Asia-Pacific |
| Key competitors |
Amoxicillin generics from Teva, Sandoz, Mylan |
Market challenges and trends
- Antibiotic resistance limits uses in certain infections.
- Increasing awareness of antibiotic stewardship reduces over-prescription.
- Growing trend toward combination therapies (e.g., amoxicillin/clavulanate).
- Rising demand in pediatric and outpatient settings.
What are the regulatory and patent considerations?
The patent for Moxatag expired by 2013, allowing generic manufacturers to produce equivalent formulations. GSK's patent strategy centered on extended-release formulations, which has since faced patent cliff exposure.
- Regulatory status: No recent FDA approvals or supplemental NDAs for Moxatag.
- Patent status: Expired; no form of exclusivity remains.
- Policy influences: Antibiotic stewardship programs influence prescribing behaviors.
What is the future market outlook?
The prospects for Moxatag as a branded product are limited. However, the amoxicillin market remains robust in the context of generic competition.
Key factors influencing future projections:
- Generic dominance: The market favors low-cost generics over branded products.
- Innovation potential: No significant pipeline for reformulations or new indications.
- Regulatory environment: Increased scrutiny and usage restrictions in some regions.
- Emerging markets: Growing demand for affordable antibiotics drives volume sales.
The overall amoxicillin market is projected to sustain moderate growth, with the branded segment relying chiefly on established, non-patent-protected formulations. If GSK or other firms pursue combination therapies or novel formulations, new clinical trials could emerge; however, current activity appears minimal.
Summary and implications for stakeholders
- Investors: Focus on generics market segments; branded Moxatag's outlook is limited.
- Manufacturers: Opportunities exist in emerging markets via affordable generics.
- Regulators: Continued emphasis on combating antibiotic resistance.
Key takeaways
- Moxatag has no active clinical trials; the product relies on off-patent formulations.
- The amoxicillin market globally reaches approximately $1.2 billion, growing steadily.
- Patent expirations have permitted broad generic competition.
- Future growth depends on market demand for generics rather than new clinical programs.
- Regulatory focus on antibiotic stewardship may restrain market expansion.
FAQs
1. Are there any ongoing clinical trials for Moxatag?
No. There are no known ongoing clinical trials exclusively for Moxatag.
2. Can new formulations of amoxicillin be approved?
Yes. Companies can develop and seek approval for reformulations or combination therapies. Some patents related to specific formulations may still be active.
3. How does antibiotic resistance affect the amoxicillin market?
Resistance reduces the efficacy for certain infections, limiting prescribing and impacting sales volume.
4. Is there potential for Moxatag to regain market share?
Unlikely, given the expiration of patents and existing competition from generics.
5. What are the key drivers for the amoxicillin market's future?
Growing global healthcare needs, especially in emerging markets, and the ongoing demand for affordable antibiotics.
References
- Market Research Future. (2022). Amoxicillin Market Trends and Forecasts.
- US Food and Drug Administration. (2023). Drug Approvals and Labeling.
- GlobalData. (2023). Antibiotics Market Forecast.
- GSK. (2010). Moxatag patent and regulatory filings.
- World Health Organization. (2021). Antibiotic stewardship and resistance.
